The proposed 100 per cent tariff on branded and patented pharmaceutical imports is unlikely to have an immediate impact on Indian exports, as the bulk of our contribution lies in simple generics Published on :

Trump’s 100% tariff move on branded drugs may not impact India’s pharma exports significantly

Hyderabad: The United States has proposed a 100 per cent tariff on branded and patented pharmaceutical imports, raising concerns over global medicine supply chains.

While the announcement could impact multinational companies, Indian pharmaceutical exports are expected to remain largely stable, given the country’s strong presence in the generics market and existing US-based operations.

India’s role in the US pharmaceutical market

India supplies nearly 47 per cent of the United States’ p

See Full Page